Results 291 to 300 of about 867,189 (360)

Histidine-improved cancer immunosurveillance. [PDF]

Oncoimmunology
Fidelle M, Reich E, Zitvogel L, Kroemer G.   +3 more
europepmc   +1 more source

High-risk features in adult patients with B-cell acute lymphoblastic leukemia: redefining risk in the era of targeted immunotherapy. [PDF]

Blood Res
Baek DW.
europepmc   +1 more source

Corrigendum to "CD39+CD8+ T cell infiltration is associated with clinical outcomes of subsequent immunotherapy in advanced EGFR-mutant non-small cell lung cancer". [PDF]

Ther Adv Med Oncol
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tertiary lymphoid structures improve immunotherapy and survival in melanoma

Nature, 2020
Lars Bastholt, Kristian Pietras
exaly   +2 more sources

Mechanisms and biomarkers of subcutaneous immunotherapy and sublingual immunotherapy in allergen immunotherapy

Allergy and Asthma Proceedings, 2022
There are currently no biomarkers that can accurately predict clinical outcomes and segregate responders from nonresponders in allergen immunotherapy (AIT). Therefore, identifying a reliable predictive biomarker is essential to enable clinicians to tailor personalized therapy.
Tiak Ju, Tan, Janice A, Layhadi, Mohamed H, Shamji   +2 more
openaire   +2 more sources

Immunotherapy in cholangiocarcinoma

Current Opinion in Gastroenterology, 2021
Purpose of review Cholangiocarcinoma is an aggressive heterogeneous group of cancers of the biliary epithelium and most patients are detected with advanced metastatic disease with poor prognosis. The therapeutic options are limited, and the current standard care as systemic therapy is still cytotoxic chemotherapy.
Raed, Al-Rajabi, Weijing, Sun
openaire   +2 more sources